| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c6d79f70dd005120c0670419fe090ad9 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-8146
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-544
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-549
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-62 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-81 |
| filingDate |
2013-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a534852b42dfd80d6596add0fde5e5a5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d5588ecfbabbb7ff98b964b3579646da |
| publicationDate |
2013-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2013240326-A |
| titleOfInvention |
Tissue inhibitors of metalloproteinases linked to glycosylphosphatidylinositol (GPI) anchors for the treatment of cancer and skin lesions |
| abstract |
A fusion construct comprising an amino acid sequence of a tissue inhibitor of metalloproteinase (TIMP) or a biologically active fragment thereof, wherein the TIMP or biologically active fragment thereof is linked to a mucin domain followed by a glycosylphosphatidylinositol (GPI) anchor. A fusion construct that is linked. The fusion construct is administered for the treatment of cancer. [Effect] GPI-anchored TIMP protein is incorporated into the surface membrane of tumor cells and makes the tumor cells susceptible to FAS-induced apoptosis. Furthermore, the fusion construct is an effective agent useful for wound healing applications. In one embodiment, TIMP is linked to a mucin followed by GPI to enhance cell presentation. The use of GPI to link TIMPs makes the resulting fusion protein particularly useful as an anti-cancer agent for the treatment of cancer, particularly any residual cancer after incomplete surgical resection of the primary tumor in an individual . [Selection figure] None |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020523130-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7346307-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016214580-A |
| priorityDate |
2005-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |